Liam C. Woerner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liam C. Woerner has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Daniel E. Johnson
Department of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA
5 shared publications - Jacqueline P. Nguyen
Department of Otolaryngology–Head and Neck Surgery, University of California, San Francisco, California
5 shared publications - Jennifer R. Grandis
Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, CA, USA
5 shared publications - Kelly Blum
Department of Epidemiology and Biostatistics, University of California, San Francisco, California
5 shared publications - Marius Hoerner
Department of Oral and Maxillofacial Plastic Surgery and Head and Neck Surgery, University Hospital Würzburg, Würzburg, Germany
5 shared publications - Mi-Ok Kim
Department of Epidemiology and Biostatistics, University of California, San Francisco, California
5 shared publications
Latest Publications
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most common alterations in head and neck squamous cell carcinoma (HNSCC). PTEN negatively regulates PI3K signaling and its downstream effectors including COX2. COX2 mediates the synthesis of prostaglandin E2 (PGE2) which contributes to immunosuppression in the tumor microenvironment. PGE2 also binds to one or more EP receptors (EP1–EP4) and promotes the growth of tumor cells via activation of EP2 and EP4. However, the role of PGE2 in PTEN-deficient HNSCC is incompletely understood. In this study, we assessed PGE2 signaling in PTEN-deficient HNSCC and evaluated the effect of aspirin or TPST-1495, a dual EP2/EP4 antagonist, on the growth of PTEN knockout and PIK3CA-altered HNSCC tumors in immunocompetent mice. Our results demonstrated that aspirin selectively inhibits the growth of PTEN knockout HNSCC tumors. TPST-1495 inhibited tumor growth and substantially increased the antitumor activity of the immune checkpoint inhibitor anti-PD1. To date, there are no FDA-approved therapies for PI3K pathway–altered HNSCC. Our findings suggest that NSAIDs demonstrate antitumor activity in PTEN-deficient or PI3K-altered tumors whereas EP2/EP4 targeting may augment FDA-approved anti-PD1 therapy in HNSCC.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most common alterations in head and neck squamous cell carcinoma (HNSCC). PTEN negatively regulates PI3K signaling and its downstream effectors including COX2. COX2 mediates the synthesis of prostaglandin E2 (PGE2) which contributes to immunosuppression in the tumor microenvironment. PGE2 also binds to one or more EP receptors (EP1–EP4) and promotes the growth of tumor cells via activation of EP2 and EP4. However, the role of PGE2 in PTEN-deficient HNSCC is incompletely understood. In this study, we assessed PGE2 signaling in PTEN-deficient HNSCC and evaluated the effect of aspirin or TPST-1495, a dual EP2/EP4 antagonist, on the growth of PTEN knockout and PIK3CA-altered HNSCC tumors in immunocompetent mice. Our results demonstrated that aspirin selectively inhibits the growth of PTEN knockout HNSCC tumors. TPST-1495 inhibited tumor growth and substantially increased the antitumor activity of the immune checkpoint inhibitor anti-PD1. To date, there are no FDA-approved therapies for PI3K pathway–altered HNSCC. Our findings suggest that NSAIDs demonstrate antitumor activity in PTEN-deficient or PI3K-altered tumors whereas EP2/EP4 targeting may augment FDA-approved anti-PD1 therapy in HNSCC.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 2 shows Elevated COX2 protein expression in PTEN-deficient HNSCC cells. COX2 protein expression in PTEN knockout (PTEN KO) in Cal27 human and MOC22 murine cells was increased compared to parental cells.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 2 shows Elevated COX2 protein expression in PTEN-deficient HNSCC cells. COX2 protein expression in PTEN knockout (PTEN KO) in Cal27 human and MOC22 murine cells was increased compared to parental cells.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 1 shows that loss of PTEN increases tumor growth. Tumor cells derived from MOC1 cells with PTEN loss or PIK3CA amplification (WT) or mutation (H1047R, E545K) were implanted subcutaneously in immunocompetent mice and tumor volumes were monitored for 19 days. Tumor volumes for MOC1 cells engineered for PIK3CA mutations H1047R (p=0.032) or E545K (p=0.0023) or PTEN KO (p=0.0079) were increased compared with tumors derived from parental control cells. The mean measurements and SD of each group are shown. * p<0.05 and ** p<0.01 determined by Dunnett’s method.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 1 shows that loss of PTEN increases tumor growth. Tumor cells derived from MOC1 cells with PTEN loss or PIK3CA amplification (WT) or mutation (H1047R, E545K) were implanted subcutaneously in immunocompetent mice and tumor volumes were monitored for 19 days. Tumor volumes for MOC1 cells engineered for PIK3CA mutations H1047R (p=0.032) or E545K (p=0.0023) or PTEN KO (p=0.0079) were increased compared with tumors derived from parental control cells. The mean measurements and SD of each group are shown. * p<0.05 and ** p<0.01 determined by Dunnett’s method.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 3 shows that TPST-1495 enhances anti-PD1 anti-tumor activity. MOC1 cells engineered to express E545K PIK3CA mutation (2x106 cell/mouse) were implanted subcutaneously into flanks of immunocompetent C57BL/6 mice. Once tumors were palpable (about 100 mm3; approximately 10 days), mice were treated with vehicle (methylcellulose bi-daily and/or IgG), TPST-1495 (150 mg/kg, bi-daily), anti-PD1 (0.2 mg per mouse on days 1, 4, and 7 after palpable tumors were established), or the combination of TPST-1495 and anti-PD1 (n=5 per group). Concomitant administration of TPST-1495 and anti-PD1 showed an additive effect on tumor growth inhibition compared to anti-PD1 (p=0.001) alone. The mean measurements and SEM of each group are shown. * p<0.05 and ** p<0.01 determined by Dunnett’s method.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 3 shows that TPST-1495 enhances anti-PD1 anti-tumor activity. MOC1 cells engineered to express E545K PIK3CA mutation (2x106 cell/mouse) were implanted subcutaneously into flanks of immunocompetent C57BL/6 mice. Once tumors were palpable (about 100 mm3; approximately 10 days), mice were treated with vehicle (methylcellulose bi-daily and/or IgG), TPST-1495 (150 mg/kg, bi-daily), anti-PD1 (0.2 mg per mouse on days 1, 4, and 7 after palpable tumors were established), or the combination of TPST-1495 and anti-PD1 (n=5 per group). Concomitant administration of TPST-1495 and anti-PD1 showed an additive effect on tumor growth inhibition compared to anti-PD1 (p=0.001) alone. The mean measurements and SEM of each group are shown. * p<0.05 and ** p<0.01 determined by Dunnett’s method.
- 20 February 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (6) , 931-941
Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most common alterations in head and neck squamous cell carcinoma (HNSCC). PTEN negatively regulates PI3K signaling and its downstream effectors including COX2. COX2 mediates the synthesis of prostaglandin E2 (PGE2) which contributes to immunosuppression in the tumor microenvironment. PGE2 also binds to one or more EP receptors (EP1–EP4) and promotes the growth of tumor cells via activation of EP2 and EP4. However, the role of PGE2 in PTEN-deficient HNSCC is incompletely understood. In this study, we assessed PGE2 signaling in PTEN-deficient HNSCC and evaluated the effect of aspirin or TPST-1495, a dual EP2/EP4 antagonist, on the growth of PTEN knockout and PIK3CA-altered HNSCC tumors in immunocompetent mice. Our results demonstrated that aspirin selectively inhibits the growth of PTEN knockout HNSCC tumors. TPST-1495 inhibited tumor growth and substantially increased the antitumor activity of the immune checkpoint inhibitor anti-PD1. To date, there are no FDA-approved therapies for PI3K pathway–altered HNSCC. Our findings suggest that NSAIDs demonstrate antitumor activity in PTEN-deficient or PI3K-altered tumors whereas EP2/EP4 targeting may augment FDA-approved anti-PD1 therapy in HNSCC.
- 20 February 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (6) , 931-941
Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most common alterations in head and neck squamous cell carcinoma (HNSCC). PTEN negatively regulates PI3K signaling and its downstream effectors including COX2. COX2 mediates the synthesis of prostaglandin E2 (PGE2) which contributes to immunosuppression in the tumor microenvironment. PGE2 also binds to one or more EP receptors (EP1–EP4) and promotes the growth of tumor cells via activation of EP2 and EP4. However, the role of PGE2 in PTEN-deficient HNSCC is incompletely understood. In this study, we assessed PGE2 signaling in PTEN-deficient HNSCC and evaluated the effect of aspirin or TPST-1495, a dual EP2/EP4 antagonist, on the growth of PTEN knockout and PIK3CA-altered HNSCC tumors in immunocompetent mice. Our results demonstrated that aspirin selectively inhibits the growth of PTEN knockout HNSCC tumors. TPST-1495 inhibited tumor growth and substantially increased the antitumor activity of the immune checkpoint inhibitor anti-PD1. To date, there are no FDA-approved therapies for PI3K pathway–altered HNSCC. Our findings suggest that NSAIDs demonstrate antitumor activity in PTEN-deficient or PI3K-altered tumors whereas EP2/EP4 targeting may augment FDA-approved anti-PD1 therapy in HNSCC.